Prostaglandin E1
Vasodilator / PGE1 is an endogenous prostaglandin with vasodilatory, anti-platelet, and, anti-hypertensive activities.1,2 It is in clinical use for the treatment of erectile dysfunction3 and the emergency management of infants with patent ductus arteriosus4. It has also been used in the treatment of peripheral arterial occlusive disease (PAD).5
Biochemicals & reagents
745-65-3
PGE1; Alprostadil
1) Kirtland (1988) Prostaglandin E1: 1 review; Prostaglandins Leukot.Essent.Fatty Acids; 32 165 2) Schermuly et al. (2005) Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension; Curr.Top.Dev.Biol. 67 251 3) Urciuoli et al (2004) Prostaglandin E1 for treatment of erectile dysfunction; Cochrane Database Syst.Rev. CD001784 4) Huang et al. (2013) Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation; Pediatr.Neonatol. 54 102 5) Schroer and Hohlfeld (2004) Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease; Vasa 33 119
-20°C
TARGET: GPCR -- PATHWAY: Coagulation; Lipid signaling -- DISEASE AREA: Hypertension